New anemia therapies: Translating novel strategies from bench to bedside

American Journal of Kidney Diseases

Volumn 59, Issue 3, 2012, Pages 444-451

  MacDougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anemia; chronic kidney disease; erythropoietin gene therapy; GATA 2 inhibitors; hepcidin; HIF stabilizers; peginesatide

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEPCIDIN; HEXAL; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; PROTEASOME; RECOMBINANT ERYTHROPOIETIN; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; GENE EXPRESSION; GENE THERAPY; HUMAN; IRON METABOLISM; NONHUMAN; REVIEW; TREATMENT OUTCOME; UPREGULATION;

ANEMIA; ANIMALS; CHRONIC DISEASE; GENE THERAPY; HEMATINICS; HUMANS; KIDNEY DISEASES; PEPTIDES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84857371377     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.11.013     Document Type: Review

References (47)

1. G. Mayer, J. Thum, E.M. Cada, H.K. Stummvoll, H. Graf Working capacity is increased following recombinant human erythropoietin treatment Kidney Int 34 1988 525 528
2. I.C. Macdougall, N.P. Lewis, M.J. Saunders Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin Lancet 335 1990 489 493 (Pubitemid 20073052)
3. R.W. Evans, B. Rader, D.L. Manninen The quality of life of hemodialysis recipients treated with recombinant human erythropoietin Cooperative Multicenter EPO Clinical Trial Group JAMA 263 1990 825 830 (Pubitemid 20050894)
4. J.T. Marsh, W.S. Brown, D. Wolcott rHuEPO treatment improves brain and cognitive function of anemic dialysis patients Kidney Int 39 1991 155 163
5. M.P. Curran, P.L. McCormack Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease Drugs 68 2008 1139 1156 (Pubitemid 351693680)
6. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590 (Pubitemid 28385655)
7. P.S. Parfrey, R.N. Foley, B.H. Wittreich Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease J Am Soc Nephrol 16 2005 2180 2189 (Pubitemid 41716451)
8. T.B. Dreke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 335 2006 2071 2084 (Pubitemid 44749316)
9. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 335 2006 2085 2098 (Pubitemid 44749317)
10. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
11. R.D. Kilpatrick, C.W. Critchlow, S. Fishbane Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients Clin J Am Soc Nephrol 3 2008 1077 1083
12. L.A. Szczech, H.X. Barnhart, J.K. Inrig Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes Kidney Int 74 2008 791 798
13. S.D. Solomon, H. Uno, E.F. Lewis Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
14. N.D. Vaziri, X.J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol Dial Transplant 24 2009 1082 1088
15. N.C. Wrighton, F.X. Farrell, R. Chang Small peptides as potent mimetics of the protein hormone erythropoietin Science 273 1996 458 464
16. I.C. Macdougall Hematide, a novel peptide-based erythropoiesis- stimulating agent for the treatment of anemia Curr Opin Investig Drugs 9 2008 1034 1047
17. Q. Fan, K.K. Leuther, C.P. Holmes Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia Exp Hematol 34 2006 1303 1311 (Pubitemid 44389891)
18. K.W. Woodburn, Q. Fan, S. Winslow Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model Exp Hematol 35 2007 1201 1208 (Pubitemid 47088782)
19. I.C. Macdougall, J. Rossert, N. Casadevall A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia N Engl J Med 361 2009 1848 1855
20. I.C. Macdougall, A. Wiecek, B. Tucker Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients Clin J Am Soc Nephrol 6 11 2011 2579 2586
21. S. Fishbane, A. Besarab, B. Schiller et al. Primary safety and efficacy results from four Phase 3 randomized, active-controlled, open-label studies of Hematide™/ Peginesatide among CKD dialysis and non-dialysis patients Proceedings of the American Society of Nephrology Renal Week November 16-21, 2010 Denver, CO. Abstract LB-FC4
22. W. Jelkmann Molecular biology of erythropoietin Intern Med 43 2004 649 659 (Pubitemid 39264162)
23. C.J. Schofield, P.J. Ratcliffe Oxygen sensing by HIF hydroxylases Nat Rev Mol Cell Biol 5 2004 43 54
24. M. Nangaku, K.U. Eckardt Pathogenesis of renal anemia Semin Nephrol 26 2006 261 268 (Pubitemid 44722454)
25. M. Nangaku, I. Kojima, T. Tanaka, T. Ohse, H. Kato, T. Fujita Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase Recent Patent Rev Cardiovasc Drug Disc 1 2006 129 139
26. P. Urquilla, A. Fong, S. Oksanen Upregulation of endogenous EPO in healthy subjects by inhibition of HIF-PH [abstract] J Am Soc Nephrol 15 2004 546A
27. W.M. Bernhardt, M.S. Wiesener, P. Scigalla Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD J Am Soc Nephrol 21 2010 2151 2156
28. V.H. Haase Hypoxic regulation of erythropoiesis and iron metabolism Am J Physiol Renal Physiol 299 2010 F1 F13
29. Astellas Pharma Inc. Adverse event of FG-2216 for the treatment of anemia Media Release May 07, 2007 http://www.astellas.com/global/about/news/2007/pdf/ 070507-eg.pdf Accessed October 15, 2011
30. A. Besarab, H.N. Hulter, S. Klaus FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients American Society of Nephrology Congress 2010 Denver, CO; SA-FC416
31. S. Toffoli, A. Roegiers, O. Feron Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1 Angiogenesis 12 2009 47 67
32. GlaxoSmithKline pipeline 1278863 prolyl hydroxylase inhibitor for anaemia associated with chronic renal disease http://www.gsk.com/investors/product- pipeline/docs/gsk-pipeline-2011.pdf Accessed May 29, 2011
33. Bayer pipeline news BAY 85-3934. HIF PH inhibitor in phase I trials for anemia in chronic kidney disease http://www.press.bayer.com/baynews/baynews.nsf/ id/2010-1515-e Accessed May 29, 2011
34. R. Shalwitz, C. Hartman, C. Finn, I. Shalwitz, D.K. Logan AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total binding capacity in healthy adults Proceedings of the American Society of Nephrology Kidney Week November 8-13, 2011 Philadelphia, PA. Abstract FR-OR186
35. M.V. Verga Falzacappa, M.U. Muckenthaler Hepcidin: iron-hormone and anti-microbial peptide Gene 364 2005 37 44 (Pubitemid 41773232)
36. J.L. Babitt, H.Y. Lin Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD Am J Kidney Dis 55 2010 726 741
37. I.C. Macdougall, J. Malyszko, R.C. Hider, S.S. Bansal Current status of the measurement of blood hepcidin levels in chronic kidney disease Clin J Am Soc Nephrol 5 2010 1681 1689
38. E. Nemeth, M.S. Tuttle, J. Powelson Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306 2004 2090 2093 (Pubitemid 40007660)
39. E.H. Kemna, H. Tjalsma, H.L. Willems, D.W. Swinkels Hepcidin: from discovery to differential diagnosis Haematologica 93 2008 90 97 (Pubitemid 351156156)
40. B.J. Sasu, K.S. Cooke, T.L. Arvedson Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia Blood 115 2010 3616 3624
41. Noxxon Pharma AG pipeline NOX-H94, 44-nucleotide l-RNA oligonucleotide linked to 40 kDa PEG http://www.noxxon.com/index.php?option=com- content&view=article&id=88&Itemid=100 Accessed May 29, 2011
42. S. Imagawa, M. Yamamoto, Y. Miura Negative regulation of the erythropoietin gene expression by the GATA transcription factors Blood 89 1997 1430 1439 (Pubitemid 27080008)
43. E. Ingley, P.A. Tilbrook, S.P. Klinken New insights into the regulation of erythroid cells IUBMB Life 56 2004 177 184 (Pubitemid 38828745)
44. S. Imagawa, Y. Nakano, N. Obara A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA FASEB J 17 2003 1742 1744
45. Y. Nakano, S. Imagawa, K. Matsumoto Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease Blood 104 2004 4300 4307 (Pubitemid 39620186)
46. E. Brill-Almon, B. Stern, D. Afik Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins Mol Ther 12 2005 274 282 (Pubitemid 41025097)
47. Medgenics press release April 27, 2010 Medgenics granted approval for extension of anaemia trial http://www.medgenics.com/downloads/Announcement-MOH- 270410.pdf Accessed October 15, 2011